An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new piece in Pharmacy Times argues that pharmacists play a key role in making sure people with chronic kidney disease (CKD) get the benefits of two classes of drugs: SGLT2 inhibitors and GLP-1 receptor agonists. The article isn't announcing a new drug. It's about who should be helping patients access and use these medicines safely and effectively. SGLT2 inhibitors and GLP-1 receptor agonists are two types of medications that started in diabetes care but also help protect the kidneys and heart. In plain terms: SGLT2 inhibitors help the kidneys get rid of extra sugar and can reduce how much strain the kidneys and heart are under. GLP-1 receptor agonists mimic a natural gut signal that makes you feel full and helps control blood sugar, and some evidence suggests they also protect the heart and possibly the kidneys. These are prescription drugs, and they often need dose checks, monitoring for side effects, and coordination with other medications — tasks pharmacists are trained to do. What the article highlights is practical, not a clinical trial: pharmacists can identify patients who should be considered for these drugs, help manage insurance and cost issues, adjust doses when kidney function changes, watch for interactions, and educate patients about side effects and what to expect. The claim is based on the professional role pharmacists already play and on growing guideline recommendations that more people with CKD should be offered these medicines. The piece likely cites examples or expert opinion rather than new clinical data; it’s about implementation and care coordination rather than proving the drugs work — we already have trials showing benefits for many patients. This matters because many people with CKD are not yet getting these medications despite guideline support. For a person with kidney disease or diabetes, that gap can mean missed chances to slow kidney decline or reduce heart risks. If pharmacists are more involved, patients might get started on the right medicine sooner, avoid dangerous drug combinations, and have fewer interruptions because of insurance or dosing problems. For families and primary care clinics, it means one more trained professional actively looking out for safer, evidence-based treatment. There are caveats. These medicines have side effects: SGLT2 inhibitors can increase risk of urinary or genital infections and require attention to hydration; GLP-1 drugs commonly cause nausea and can affect appetite and weight. Dosing and safety depend on kidney function, so careful monitoring is essential. The article is about expanding pharmacists’ roles, which raises questions about local regulations, training, and who makes final prescribing decisions. Also, not every patient is a candidate for these drugs, and insurance or cost barriers remain real. Bottom line: pharmacists can be an important bridge to get appropriate SGLT2 and GLP-1 treatments to people with chronic kidney disease, helping with suitability checks, monitoring, and access — but careful oversight and individualized decisions are still necessary.
Source: Pharmacy Times